Elafra

There is no image.

Leflunomide

Method of action: Anti-Inflammatory, Antiproliferative, Immunomodulating, Immunosuppressive

Treatment option: Arthritis,Osteoarthritis, Psoriatic Arthritis, Rheumatoid Arthritis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Elafra

What is Elafra? (Leflunomide)

Property	Description
Active ingredient	Leflunomide
Form	Oral tablets (Film-coated)
Pharmacological class	Disease-Modifying Anti-Rheumatic Drug (DMARD); Immunosuppressant
General purpose	To modify and slow chronic inflammatory processes
Origin	Synthetic (Isoxazole derivative)

What Type of Medicine Is Elafra (Leflunomide)?

Elafra is a prescription-only, synthetic medication classified as a Disease-Modifying Anti-Rheumatic Drug (DMARD), with the active ingredient being Leflunomide. Leflunomide is designated as an immunosuppressive agent. This means the medicine works by regulating an overactive immune response, a recognized benefit for managing certain systemic inflammatory conditions. It is a systemic treatment, intended to affect processes throughout the entire body. The drug belongs to the non-biological DMARD group and is chemically defined as an isoxazole derivative that functions as a prodrug, converting into its active metabolite once metabolized.

Elafra's Composition and Physical Form

The medication is supplied as a single-ingredient product in the form of oral tablets, which are typically film-coated for ingestion. As an oral preparation, the Leflunomide substance is combined with necessary solid excipients to create the final solid dosage form, allowing for precise delivery of the medication. This compound provides a targeted immunomodulatory action. In simple terms, this signifies that the medicine works internally to help control the body's inflammatory cycles through a controlled, convenient method of delivery.

What Is the General Purpose of an Immunomodulatory Agent?

The general purpose of Elafra is to exert an immunomodulatory action that aims to modify or slow the progression of chronic inflammatory processes within the body, such as those seen in active rheumatoid arthritis. Its action is fundamentally aimed at stabilizing or slowing down the progression of the underlying condition. Its active metabolite works primarily by inhibiting a mitochondrial enzyme called dihydroorotate dehydrogenase (DHODH), which is essential for the production of pyrimidine. By selectively interfering with the growth of specific immune cells, Elafra provides a modifying effect on systemic inflammation, fulfilling its role as a fundamental disease-modifying agent.

What side effects are possible with Elafra?

Official Safety Profile of Elafra (Leflunomide)

The safety profile of Elafra is formally established through regulatory classifications that organize potential adverse reactions by frequency and the body system affected. Regulatory documents classify the most frequently reported adverse effects as Very Common (ge 10%), including diarrhea and elevated liver enzyme levels (ALT, AST). Reactions designated as Common (ge 1% to <10%) include alopecia (hair loss), rash, nausea, headache, dizziness, and hypertension. These effects involve various system-organ classes, notably Hepatobiliary, Gastrointestinal, Skin, and Nervous System disorders.

Serious Adverse Reactions and Safety Constraints

The medicine's regulatory labeling highlights several Serious Adverse Reactions. These include severe, potentially fatal Hepatotoxicity (liver injury and failure), severe Haematological effects such as agranulocytosis and pancytopenia, and rare but serious Interstitial Lung Disease (pneumonitis). Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented.

Population-Specific Constraints

Official documents impose critical constraints. Elafra is Contraindicated in pregnant women due to a high risk of teratogenicity (fetal harm). It is also restricted in patients with severe hepatic impairment and those with pre-existing severe blood disorders. Safety notes confirm that serious adverse reactions may persist long after treatment cessation due to the drug's long half-life, a factor that necessitates mandatory monitoring of liver enzymes and blood counts throughout therapy and often afterwards.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Elafra (Leflunomide) is officially documented to present with several clinical manifestations affecting different physiological systems. Documented overdose presentations may include symptoms such as diarrhea, stomach pain, extreme tiredness, weakness, pale skin, fast heartbeat, and shortness of breath.

Regulators note the potential for severe and life-threatening outcomes. These complications include fatal liver failure (hepatotoxicity), severe interstitial lung disease (which may be fatal), and central nervous system effects such as seizure and collapse.

When to seek immediate medical help: Emergency medical attention is required immediately for any suspected overdose. Emergency services (911) must be called immediately if the person is unawakened, has collapsed, or is experiencing severe trouble breathing. The Poison Control Helpline should also be contacted for urgent advice.

Overdose Management: No specific chemical antidote for Elafra is known. Overdose management focuses on the Accelerated Drug Elimination Procedure, which is officially mandated to rapidly remove the active metabolite from the body. This procedure typically involves the administration of agents such as cholestyramine or activated charcoal. Due to the slow elimination profile, careful monitoring is required, especially of liver function tests, until the toxicity is resolved. Caution is noted for populations with pre-existing liver or renal impairment, which may increase the risk of severe toxicity.

Therapeutic Uses of Elafra

Quick Facts: Elafra Uses

Management of Primary Biliary Cholangitis (PBC)
Employed as monotherapy for PBC in adults unable to tolerate UDCA
Utilized as combination therapy with ursodeoxycholic acid (UDCA) for adults with inadequate response to UDCA

Elafra is a therapeutic option used for the management of primary biliary cholangitis (PBC). This is a chronic liver condition that affects the bile ducts. The medication is indicated for use in adult patients who have confirmed PBC.

The medication is employed in two main therapeutic domains. It may be utilized as a combination treatment alongside ursodeoxycholic acid (UDCA) when adults with the condition have not had an adequate clinical response to UDCA alone. Additionally, Elafra is used as a single therapy (monotherapy) for individuals who are unable to tolerate UDCA. The drug acts on processes that contribute to the symptoms associated with the condition and may result in the reduction of key markers of disease activity, such as alkaline phosphatase (ALP) levels. Dosage and duration of therapy should be managed by a healthcare provider, and it is crucial to follow professional medical guidance for approved indications. The goal of therapy is to help manage symptoms and support patient outcomes.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Elafra (Leflunomide)

Elafra is officially indicated for use in adult patients with Primary Biliary Cholangitis (PBC). Regulatory documents strictly define the populations who may use this medicine and those who are prohibited or require conditional use.

Classification	Population/Condition
Contraindicated	Pregnant women, or females of reproductive potential not using effective contraception.
Contraindicated	Patients with severe hepatic impairment or known hypersensitivity to the drug.
Contraindicated	Patients with severe immunodeficiency states, severe hypoproteinaemia, or those taking teriflunomide.
Not Recommended	The pediatric population (under 18 years) due to unestablished safety and efficacy.
Not Recommended	Patients with pre-existing acute or chronic liver disease or impaired bone marrow function.
Conditional Use	Patients with renal insufficiency require caution, as clinical experience is limited.
Prohibited Status	Women who are breastfeeding must discontinue the drug.

The eligibility structure is defined by the strict exclusion of certain patient groups, with Contraindicated being the highest level of restriction imposed for conditions like pregnancy and severe liver disease. Eligibility is affirmed for adults, while use in children is formally not recommended.

What should I know about interactions with other medicines?

Elafra Interactions with other medicines and products

The active metabolite of Elafra (Leflunomide) is documented in regulatory labeling to interact with specific medicinal products and substances, leading to formal restrictions. Co-administration with Teriflunomide is strictly contraindicated due to the high risk of excessive exposure to the active compound.

Interaction Category	Documented Outcome or Restriction
Pharmacokinetic (PK) Interactions	Co-administration with the inducer Rifampin is shown to increase the active metabolite's plasma concentration by approximately 40%. The active metabolite may increase the exposure of substrates for CYP2C8, OAT3, BCRP, and OATP1B1/B3 transporters, and decrease the exposure of CYP1A2 substrates.
Pharmacodynamic (PD) Interactions	The use of Elafra with other hepatotoxic DMARDs (such as Methotrexate) carries an increased risk of liver injury due to additive effects. Taking Elafra with Warfarin may cause a decrease in the International Normalized Ratio (INR).
Substance and Population Notes	Alcohol consumption is recommended to be avoided due to the potential for additive hepatotoxicity. For patients identified as high risk for hepatotoxicity, regulatory documents impose a restriction recommending a specific lower dosage without an initial loading dose.

This interaction profile is defined by the compound's influence on key metabolic and transporter pathways, alongside additive toxicity concerns.

Mechanism of Action

How Elafra Works

Core Mechanism: Blocking Pyrimidine Synthesis

The active metabolite of Elafra selectively targets the mitochondrial enzyme Dihydroorotate Dehydrogenase (DHODH), reversibly inhibiting its function. This blockade affects the pyrimidine de novo synthesis pathway, a critical source of DNA and RNA building blocks (nucleotides) that are necessary for cellular division.

Selective Effect: Cytostasis in T-Cells

By limiting the nucleotide supply, the mechanism disproportionately affects activated T-lymphocytes, a key cellular component in the inflammatory response. This shortage forces these highly proliferative cells into a growth-halting state called G1 cell cycle arrest (cytostasis). This action is selective because non-lymphoid cells rely less on this pathway, permitting other cells, such as non-lymphoid cells, to utilize the salvage pathway.

Systemic Outcome: Functional Downregulation of Activity

Preventing the clonal expansion of T-cells reduces the overall pool of inflammatory cells and leads to the downregulation of pro-inflammatory cytokines (chemical messengers). This dual action modifies the associated cellular response, resulting in a functional downregulation of systemic inflammatory activity.

Dosage and Administration Information

Administration Guidelines for Elafra (Leflunomide)

Elafra is prescribed as an oral medication for the management of Rheumatoid Arthritis and Psoriatic Arthritis, administered under the supervision of specialists experienced in these conditions. The medicine is supplied as film-coated tablets in available strengths including 10 mg, 20 mg, and 100 mg. The tablets must be swallowed whole with liquid and may be taken once daily, with or without food, as ingestion timing does not affect absorption.

Standardized Dosing Regimen

Treatment follows a specific, two-phase protocol designed to achieve consistent drug levels efficiently. The regimen typically begins with a 100 mg loading dose taken once daily for the initial three-day period. This is immediately followed by the long-term maintenance dose. The standard maintenance dose is 20 mg taken once daily for the duration of therapy.

The dose may be reduced to 10 mg once daily if a patient does not tolerate the 20 mg dose. For patients identified by a physician as being at high risk for adverse effects, the initial 100 mg loading dose is omitted, and treatment commences directly at the maintenance dose. While the drug is taken daily, the therapeutic benefit is generally not observed until after four to six weeks of consistent use, with continued improvement over several months.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Elafra (Leflunomide)

Evidence for Use in Primary Biliary Cholangitis (PBC)

Research for Elafra (Leflunomide) has focused on its potential application in Primary Biliary Cholangitis (PBC), which is a condition marked by functional limitations and systemic imbalance. Studies have been conducted to understand the research patterns associated with this medicine. These efforts included Randomized Controlled Trials (RCTs) and extended observation studies that monitored patients over defined time intervals. Researchers specifically examined adult patients who had already demonstrated an inadequate response to standard treatments or those who were unable to tolerate those treatments. The outcomes related to physiological strain or stress were studied for, including changes in liver enzyme levels like Alkaline Phosphatase (ALP) and bilirubin, which are often used as indirect measures in this research.

Findings describe patterns observed in the studies related to measured levels of these biochemical markers. Some trials also applied in studies examining patient-reported experiences, tracking how symptoms associated with PBC, such as chronic itching (pruritus), evolved over the study periods. This evidence contributes to the broader evidence landscape by providing context for the relationship between the medicine and changes in disease markers and patient-perceived discomfort.

Investigating Monotherapy vs. Combination Use

Clinical studies were established with two distinct research scenarios. Some trials was studied for monotherapy, meaning they evaluated Elafra as a single treatment for patients who could not take other standard medications. Other research explored its use as combination therapy, where Elafra was added alongside existing standard treatments. These different research designs allowed investigators to monitor responses across varying symptom burdens and patient needs. Studies monitored outcomes in both single-use and combined treatment settings, helping to contextualize how patients reported their experience across these therapeutic approaches.

Long-Term Evidence and Durability of Follow-up

The majority of the available findings that describe changes measured during the study period are based on intermediate follow-up durations, often up to 12 months. This research provides insight into short-term changes and how outcomes related to systemic imbalance evolve during the first year of observation. Beyond this period, data is typically collected through long-term open-label extension studies, where patients are continuously monitored outside the initial randomized trial structure.

However, there is limited information for long-term outcomes regarding the medicine’s sustained influence on crucial patient outcomes, such as rates of liver transplantation or overall patient survival. The certainty remains low regarding the duration and durability of observed patterns over several years, as these types of hard clinical endpoints require prolonged observation periods, and long-term effects are not fully established.

Evidence in Specific Patient Populations

The research has primarily focused on the general adult population with confirmed PBC. Consequently, data for certain groups remain insufficient. For instance, evidence is limited regarding the use of Elafra in specific populations, such as pediatric patients or those with certain comorbid conditions that were excluded from the initial trials. The results apply only to the populations studied, meaning the applicability of these findings to individuals with different health profiles is not comprehensively documented in current regulatory evidence.

What is Still Uncertain About the Research for Elafra

A primary uncertainty noted in scientific review is the reliance on indirect measures (surrogate outcomes) as the main outcomes for regulatory evaluation. While the research monitored shifts in these markers, they are considered indirect evidence. Therefore, the findings describe group patterns, not personal outcomes, and certainty remains low regarding their direct link to long-term outcomes like improved survival or reduced need for liver transplantation.

Furthermore, follow-up durations were limited in many of the initial randomized studies, meaning the patterns observed when the medicine is used over many years are not fully characterized. Regulatory bodies often indicate that research is ongoing to gather more comprehensive long-term data needed to confirm the durability and impact of the medicine on final clinical outcomes. This evidence highlights what is known—and what is still uncertain—about the medicine's role in the full progression of the condition.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Elafra (FAQ)

Q: Is Elafra a long-term treatment or a short-term one?

Official dosing instructions are provided for the duration of therapy, suggesting its intended use is a long-term treatment for chronic conditions. Clinical studies have examined the use of the medicine for periods lasting up to two years.

Q: Are there any common foods or drinks that interact with Elafra?

Regulatory documents recommend avoiding alcohol consumption due to the potential for an increased risk of liver injury when combined with this medicine. The official administration guidelines state that the medicine may be taken with or without food.

Q: Are there specific times of day that Elafra is usually taken?

The official administration instructions state the medicine is taken once daily, with or without food. Regulatory instructions emphasize consistent daily administration for maintaining stable medicine levels in the body, and the time of day is determined by the prescribing healthcare provider.

Q: Are there ongoing clinical trials for new uses of Elafra?

Regulatory bodies often indicate that research is ongoing to gather more comprehensive data about the medicine's sustained influence on final clinical outcomes, such as its effects over many years. This research is generally focused on better understanding the medicine's established uses.

Q: What does the drug classification of Elafra mean?

The medicine is described in authoritative sources as belonging to a class of medications called Disease-Modifying Antirheumatic Drugs (DMARDs). DMARDs are designed to modify or slow the progression of inflammatory conditions.

Q: Do I need to avoid alcohol completely while taking Elafra?

Official documents recommend avoiding alcohol consumption due to the potential for an increased risk of liver injury when used with the medicine. This is a caution against a possible additive effect, especially as the medicine requires mandatory monitoring of liver enzymes.

Q: Does Elafra affect the results of common lab tests?

Official safety notes state that mandatory monitoring of liver enzymes (ALT, AST) and blood counts is necessary throughout therapy and often afterwards. This is due to the potential for the medicine to cause changes in these blood tests.

Q: Why do some people stop taking Elafra after a while?

In clinical studies, reasons for patients discontinuing the medicine included both lack of efficacy (the medicine not working as intended) and safety concerns (adverse effects). This is common for many long-term treatments, where benefit and tolerability must be balanced.

Q: What does 'contraindicated' mean in the context of Elafra's use?

A contraindication describes a condition or factor that serves as a reason to withhold a certain medical treatment due to the high risk of serious harm. For this medicine, being pregnant is a contraindication because of the known high risk of fetal harm.

Q: How long does Elafra stay in the body after the last dose?

The active metabolite of the medicine has a very long half-life, meaning it remains in the body for an extended period. Pharmacokinetic data indicates it stays in the body for approximately two weeks on average.

Q: Is it common to have stomach upset after starting Elafra?

The official safety profile lists diarrhea as a Very Common adverse effect (ge 10%) and nausea as a Common adverse effect (1% to <10%). These gastrointestinal issues are among the most frequently reported side effects in studies.

Q: If I have a rash after taking Elafra, is that always an allergic reaction?

The official safety profile lists rash as a common adverse effect, which may or may not be related to an allergy. However, the documentation also notes rare but very serious Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome.

Q: Does the efficacy of Elafra vary based on age or weight?

Population pharmacokinetic analysis indicates that pediatric patients with lower body weights (le 40 kg) have a reduced clearance of the active compound relative to adults. This data helps healthcare providers understand how dosage may need to be considered for specific populations.

Q: Is Elafra a type of antibiotic?

No, Elafra is not an antibiotic. The medicine is classified as a Disease-Modifying Antirheumatic Drug (DMARD), which acts by modifying the inflammatory response rather than treating bacterial infections.

Q: Is Elafra available over the counter in some countries?

No, authoritative drug databases list this medicine as a Prescription only (Rx) medicine. It must be administered under the direct supervision of specialists experienced in treating the relevant conditions.

Q: Can Elafra be used by people who have mild kidney problems?

Official pharmacokinetic information states the active metabolite is eliminated from the body by further metabolism and subsequent renal excretion (via the kidneys). This highlights the kidney's role in processing the medicine.

Q: Does Elafra cause drowsiness or affect my ability to drive?

Official safety documents list adverse effects such as dizziness and vertigo among the common reports. The official documentation lists these effects, which may potentially impact alertness. Patients should be aware of these reported side effects.

Q: What happens if I forget to take a dose of Elafra, and should I take two the next time?

Regulatory guidance addresses situations involving missed doses by stating that the missed dose should generally be taken as soon as it is remembered. However, no patient should ever take two doses at the same time to make up for a forgotten one.

Q: Is Elafra a controlled substance or habit-forming?

The medicine is not classified as a controlled substance in the Controlled Substances Act (CSA) schedule. It is also not considered habit-forming.

Q: Do the official documents list any warnings about mental health changes with Elafra?

Less common adverse effects, or those where the incidence is not known, include post-marketing reports of anxiety and confusion. Official documents list these reports to ensure that patients are aware of the possibility of these less common effects.

Q: Is Elafra safe to take if I have a history of heart rhythm issues?

Official documentation lists cardiovascular-related effects such as tachycardia (fast heartbeat) and palpitation among postmarketing reports.

Q: Are there different brand names for the same medicine, Elafra?

Yes, the generic compound, leflunomide, is also marketed under the brand name Arava. Both medications contain the same active ingredient.

Q: Does Elafra affect fertility in men or women?

For men, updated professional guidelines state that there is no reason for men who are taking the medicine to avoid conceiving a child with their partner. The use of the medicine is contraindicated in pregnant women due to the high risk of fetal harm.

Q: What are the official restrictions for using Elafra in women who are breastfeeding?

The official product label recommends that women who are breastfeeding should not use this medication. This restriction is in place due to the potential for risk to the nursing child.

Q: How long does the effect of one dose of Elafra typically last?

Pharmacokinetic data shows that peak levels of the active metabolite in the blood occur between 6 and 12 hours after taking a single dose. However, because the medicine has a very long half-life, the effects are sustained over time with continued daily dosing.

How should Elafra be stored and disposed of?

Storage Conditions

Elafra (Leflunomide) tablets must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted between 15 C and 30 C (59 F and 86 F). The product must be protected from moisture and light.

Handling Requirements	Disposal Requirements
Keep the container tightly closed to maintain stability.	Dispose of unused product or waste material according to local requirements.
The tablets must be kept from freezing.	Avoid discharges of product waste to sewers, drains, or waterways.
Store the medicine in a safe location, strictly out of the reach of children.	Consult a healthcare professional for specific instructions on discarding unused medicine.